Dare Bioscience Inc (DARE)

1.4900
+0.0100(+0.68%)
  • Volume:
    2,940,893
  • Bid/Ask:
    1.4600/1.5400
  • Day's Range:
    1.4300 - 1.5000

DARE Overview

Prev. Close
1.48
Day's Range
1.43-1.5
Revenue
-
Open
1.5
52 wk Range
0.95-3.85
EPS
-0.89
Volume
2,940,893
Market Cap
73.53M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
303,489
P/E Ratio
-
Beta
1.77
1-Year Change
22.13%
Shares Outstanding
49,350,077
Next Earnings Date
Nov 18, 2021
What is your sentiment on Dare Bioscience Inc?
or
Market is currently closed. Voting is open during market hours.

Dare Bioscience Inc News

Dare Bioscience Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Buy
SummaryStrong BuyStrong BuyStrong SellStrong SellNeutral

Dare Bioscience Inc Company Profile

Dare Bioscience Inc Company Profile

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women’s health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company’s Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.

Read More
  • Abbott will pay good money for Dare
    0
    • XELA next print mony
      2
      • This us one of WSB reditt stock
        0
        • Abbott will end in buying this co
          0
          • xela is next wallbets stock
            2
            • yes
              1
          • i have no experience in crude oil sorry only in equities is good to buy now Dare but if you want more advises you can ask me
            0
            • i have no experience in crude oil sorry only in equities is good to buy now Dare but if you want more advises you can ask me
              0
              • hello Chris do you have any ticker to buy any symbol to earn some money ?
                0
              • give me a signal please ?
                0
              • xela short term
                0
            • Its hardly moving after 1st 5 minutes
              0
              • the hight price target is 11 and the average target is 6
                1
                • Great stock!
                  0
                  • Great stock!
                    0
                    • it seems that this day is the day of dare
                      0
                      • 2021.06.30 Sold @ $1.95. Went up to $2.19 but came down fast
                        0
                        • 2021.05.20 PL Avg cost1.75
                          0
                          • no hope on Nasdaq now. it's better to buy bitcoin
                            0
                            • Way to 7
                              1
                              • Getting excited as it draws closer to end of march.. a bigger news coming
                                0
                            • to the moon on the near weeks
                              0
                              • lol scam dont buy. low volume
                                1
                                • Any thought on this counter??
                                  1
                                  • Consolidating with an imminent breakout soon
                                    1
                                    • Consolidating with an imminent breakout soon
                                      0
                                      • This is consolidating with an imminent breakout soon
                                        0
                                        • This is consolidating with an imminent breakout soon
                                          0
                                          • Consolidating with an imminent breakout soon..
                                            0
                                            • Y is this not moving when it has a 100 percent buy rating
                                              0
                                              • Bought at 3$ it has been such a disappointment so far
                                                0
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.